0001770252-21-000004.txt : 20210420
0001770252-21-000004.hdr.sgml : 20210420
20210420171830
ACCESSION NUMBER: 0001770252-21-000004
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210419
FILED AS OF DATE: 20210420
DATE AS OF CHANGE: 20210420
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lambert Nicole
CENTRAL INDEX KEY: 0001770252
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-26642
FILM NUMBER: 21838774
MAIL ADDRESS:
STREET 1: 320 WAKARA WAY
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MYRIAD GENETICS INC
CENTRAL INDEX KEY: 0000899923
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 870494517
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 320 WAKARA WAY
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84108
BUSINESS PHONE: 801-584-3600
MAIL ADDRESS:
STREET 1: 320 WAKARA WAY
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84108
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2021-04-19
0
0000899923
MYRIAD GENETICS INC
MYGN
0001770252
Lambert Nicole
320 WAKARA WAY
SALT LAKE CITY
UT
84108
0
1
0
0
See Remarks
Common Stock
2021-04-19
4
S
0
759
27.0089
D
135009
D
Common Stock
2021-04-19
4
S
0
5890
27.0095
D
129119
D
The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.13, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.13, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Ms. Lambert's title is Group President, Myriad Oncology, Myriad Women's Health and Myriad International.
By: Nathan A. Smith For: Nicole Lambert
2021-04-20